Search Results

assuring quality blood transfusion future hold joint meeting uk neqas btlp bbts blood bank technology sig 11 november 2014 royal college general practitioners london next euston station 10 00 16 15 registration refreshments commercial exhibition 09 00 10 00 opening welcome dr peter baker mr steve tucker chair uk neqas btlp steering committee bbt sig rules regulations stifling innovation improving practice chair mr bill chaffe 10 05 10 25 10 45 dr jonathan wallis freeman hospital newcastle mr jam

International Society for Apheresis Congress (ISFA 2015) 13th - 16th May 2015 | Cancun, MexicoISFA is the only one international society for apheresis mainly composed of individual members. Founded in 1996 to disseminate the most up-to-date apheresis technologies and their clinical applications so that all may benefit from the effort of ISFA. Almost 500 members from all over the world belong to ISFA.The main objectives of ISFA is to disseminate on an international basis the most up-to-

anti d failures information shot reports dr jane keidan thanks to tony davies shot team megan rowley clare milkins declarations affiliations declare assume audience basic understanding pathophysiology haemolytic disease fetus newborn hdfn anti d prophylaxis pregnancy passive prophylactic anti d given correct dose correct time prevent active sensitisation d antigen prevent haemolytic disease fetus newborn hdfn mechanism action prophylactic anti d unclear correct dose depends stage pregnancy size

do rules regulation improve quality jonathan wallis consultant haematologist freeman hospital newcastle tyne how filing cabinet appraisal audit revalidation reaccreditation guidelines hospital transfusion committees aarrgh parkinson s law pursuit progress c northcote parkinson 1957 work expands fill available employment royal navy parkinson s law staff capital ships officers men dockyard workers dockyard officials admiralty officials 1914 62 146 000 57 000 3249 2000 1928 20 100 000 62 439 4558 3

immune prophylactic anti d bcsh antenatal guidelines say jenny white deputy scheme manager uk neqas btlp raadp 28 34 weeks sensitisations neonatal deaths due anti d testing dilemmas effect anti d ig transfusion testing pregnancy antibody screening panel d negative cells covering clin sig antigens suitable ei blood required positive antibody screen anti d identified immune passive anti d kinetics immune anti d detectable approx 4 weeks exposure d cells reaches a peak concentration 6 8 weeks anti